

# Hyperphosphatemia - Pipeline Review, H1 2020

<https://marketpublishers.com/r/H820D43448D5EN.html>

Date: June 2020

Pages: 80

Price: US\$ 2,000.00 (Single User License)

ID: H820D43448D5EN

## Abstracts

Hyperphosphatemia - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia - Pipeline Review, H1 2020, provides an overview of the Hyperphosphatemia (Nutritional Disorders) pipeline landscape.

Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hyperphosphatemia (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperphosphatemia (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 1, 1, 3

and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hyperphosphatemia (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia (Nutritional Disorders).

The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hyperphosphatemia (Nutritional Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hyperphosphatemia (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia (Nutritional Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia (Nutritional Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hyperphosphatemia (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Hyperphosphatemia - Overview
- Hyperphosphatemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hyperphosphatemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hyperphosphatemia - Companies Involved in Therapeutics Development
- 3SBio Inc
- Ardelyx Inc
- China Nuokang Bio-Pharmaceutical Inc
- Chugai Pharmaceutical Co Ltd
- Citrigen Pharmaceuticals Inc
- J-Pharma Co Ltd
- OPKO Health Inc
- Panion & Bf Biotech Inc
- Shield Therapeutics Plc
- Unicycive Therapeutics Inc
- Vidasym Inc
- Hyperphosphatemia - Drug Profiles
- CGN-002 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- colestilan chloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- EOS-789 - Drug Profile
- Product Description

Mechanism Of Action

R&D Progress

fermagate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JPH-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanthanum polystyrene sulfonate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PT-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Hyperphosphatemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tenapanor hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UNI-494 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hyperphosphatemia - Dormant Projects

Hyperphosphatemia - Discontinued Products

Hyperphosphatemia - Product Development Milestones

Featured News & Press Releases

Jun 15, 2020: Ardelyx announces positive second data analysis from ongoing NORMALIZE phase 4 study evaluating Tenapanor in CKD patients on dialysis

Dec 04, 2019: Ardelyx reports positive data from tenapanor's Phase III CKD trial

Nov 06, 2019: Ardelyx announces presentation at Kidney Week 2019

Oct 15, 2019: Akebia files lawsuit against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia for its Iron Deficiency Anemia Indication and imposing a prior authorization requirement for its Hyperphosphatemia indication

Sep 03, 2019: Ardelyx announces positive results from the pivotal phase 3 AMPLIFY study evaluating tenapanor in dialysis patients who have uncontrolled hyperphosphatemia despite phosphate binder treatment

Mar 07, 2019: Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology

Feb 07, 2019: Ardelyx collaboration partner, Kyowa Hakko Kirin, announces initiation of a phase 2 clinical study of Tenapanor for Hyperphosphatemia patients on dialysis in Japan

Oct 26, 2018: Ardelyx presents new preclinical data demonstrating synergy between Tenapanor and Sevelamer when dosed in combination for elevated serum phosphorus

Aug 29, 2018: Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption

May 21, 2018: Ardelyx Raises \$50 Million in Loan Agreement with Solar Capital and Bridge Bank

Nov 21, 2017: Ardelyx Announces Updated Development Path for Tenapanor

Apr 18, 2017: Ardelyx To Present Tenapanor at Upcoming Spring Medical Meetings

Feb 15, 2017: Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease

Jan 06, 2017: Shield Therapeutics Provides Update on PT20

Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Hyperphosphatemia, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Hyperphosphatemia - Pipeline by 3SBio Inc, H1 2020  
Hyperphosphatemia - Pipeline by Ardelyx Inc, H1 2020  
Hyperphosphatemia - Pipeline by China Nuokang Bio-Pharmaceutical Inc, H1 2020  
Hyperphosphatemia - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020  
Hyperphosphatemia - Pipeline by Citragen Pharmaceuticals Inc, H1 2020  
Hyperphosphatemia - Pipeline by J-Pharma Co Ltd, H1 2020  
Hyperphosphatemia - Pipeline by OPKO Health Inc, H1 2020  
Hyperphosphatemia - Pipeline by Panion & Bf Biotech Inc, H1 2020  
Hyperphosphatemia - Pipeline by Shield Therapeutics Plc, H1 2020  
Hyperphosphatemia - Pipeline by Unicycive Therapeutics Inc, H1 2020  
Hyperphosphatemia - Pipeline by Vidasym Inc, H1 2020  
Hyperphosphatemia - Dormant Projects, H1 2020  
Hyperphosphatemia - Discontinued Products, H1 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Hyperphosphatemia, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

3SBio Inc  
Ardelyx Inc  
China Nuokang Bio-Pharmaceutical Inc  
Chugai Pharmaceutical Co Ltd  
Citragen Pharmaceuticals Inc  
J-Pharma Co Ltd  
OPKO Health Inc  
Panion & Bf Biotech Inc  
Shield Therapeutics Plc  
Unicycive Therapeutics Inc  
Vidasym Inc

## I would like to order

Product name: Hyperphosphatemia - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/H820D43448D5EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H820D43448D5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970